Abstract
Immune checkpoint inhibitors (ICIs) have hugely altered the first-line treatment strategies of advanced lung adenocarcinoma patients (aLUAD), especially when in combination with standard chemotherapy (Chemo). However, few registered clinical trials directly compared the efficacy of ICIs + Chemo versus bevacizumab (Bev) plus Chemo in aLUAD, while the latter has been solidly proven to enhance patients’ progression-free survival (PFS) when compared to Chemo alone in advanced non-small-cell lung cancer patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
